Jubilant Pharmova share price has plunged 4% and is presently trading at Rs 725.8.
Meanwhile, the BSE HEALTHCARE index is at 38,498.1 (up 0.9%).
Among the top losers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (down 1.7%) and CAPLIN POINT (down 1.5%).
ALEMBIC PHARMA (up 4.1%) and SUVEN PHARMACEUTICALS (up 3.5%) are among the top gainers today.
Over the last one year, Jubilant Pharmova has moved up from Rs 398.2 to Rs 725.8, registering a gain of Rs 327.6 (up 82.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,342.4 to 38,498.1, registering a gain of 46.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 97.1%), Lupin (up 92.8%) and Cadila Healthcare (up 92.4%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,511.4 (down 0.1%).
The top losers among the BSE Sensex today are Reliance Ind. (down 3.5%) and Kotak Bank (down 3.4%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.
In the meantime, NSE Nifty is at 24,515.9 (down 0.1%). Wipro and Reliance Ind. are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,795.1 to 80,511.4, registering a gain of 13,716.3 points (up 20.5%).
Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.
For the year ended March 2023, Jubilant Pharmova reported 115.7% decrease in net profit to Rs -649 million compared to net profit of Rs 4,130 million during FY22. Revenue of the company grew 2.5% to Rs 62,817 million during FY23.
The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 22.1.
Equitymaster requests your view! Post a comment on "Jubilant Pharmova Plunges 4%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!